{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:39:55Z","timestamp":1791333595805,"version":"4.3.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OV4-170645"],"award-info":[{"award-number":["OV4-170645"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["439999"],"award-info":[{"award-number":["439999"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OV4-170645"],"award-info":[{"award-number":["OV4-170645"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["439999"],"award-info":[{"award-number":["439999"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["439999"],"award-info":[{"award-number":["439999"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["OV4-170645"],"award-info":[{"award-number":["OV4-170645"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Viruses"],"DOI":"10.1038\/s44298-025-00149-2","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:57:25Z","timestamp":1756814245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct circulating autoantibodies are associated with COVID-19 hospitalization and SARS-CoV-2 neutralization activity"],"prefix":"10.1038","volume":"3","author":[{"given":"Rajesh Abraham","family":"Jacob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah O.","family":"Ajoge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altynay","family":"Shigayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arinjay","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison J.","family":"McGeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Mubareka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"149_CR1","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3181\/00379727-96-23545","volume":"96","author":"WC Robbins","year":"1957","unstructured":"Robbins, W. C., Holman, H. R., Deicher, H. & Kunkel, H. G. Complement fixation with cell nuclei and DNA in lupus erythematosus. Proc. Soc. Exp. Biol. Med. 96, 575\u2013579 (1957).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"149_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJM200108023450506","volume":"345","author":"A Davidson","year":"2001","unstructured":"Davidson, A. & Diamond, B. Autoimmune diseases. N. Engl. J. Med. 345, 340\u2013350 (2001).","journal-title":"N. Engl. J. Med."},{"key":"149_CR3","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.autrev.2004.07.011","volume":"3","author":"IR Mackay","year":"2004","unstructured":"Mackay, I. R. & Rowley, M. J. Autoimmune epitopes: autoepitopes. Autoimmun. Rev. 3, 487\u2013492 (2004).","journal-title":"Autoimmun. Rev."},{"key":"149_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155873","volume":"154","author":"L Mobasheri","year":"2022","unstructured":"Mobasheri, L. et al. SARS-CoV-2 triggering autoimmune diseases. Cytokine 154, 155873 (2022).","journal-title":"Cytokine"},{"key":"149_CR5","doi-asserted-by":"crossref","unstructured":"Smatti, M. K. et al. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses 11 (2019).","DOI":"10.3390\/v11080762"},{"key":"149_CR6","doi-asserted-by":"publisher","unstructured":"Puel, A., Bastard, P., Bustamante, J. & Casanova, J. L. Human autoantibodies underlying infectious diseases. J. Exp. Med. 219, https:\/\/doi.org\/10.1084\/jem.20211387 (2022).","DOI":"10.1084\/jem.20211387"},{"key":"149_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1177\/0961203317731532","volume":"27","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab, N., Talathi, S., Lopez-Olivo, M. A. & Suarez-Almazor, M. E. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 27, 572\u2013583 (2018).","journal-title":"Lupus"},{"key":"149_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25509-3","volume":"12","author":"SE Chang","year":"2021","unstructured":"Chang, S. E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021).","journal-title":"Nat. Commun."},{"key":"149_CR9","doi-asserted-by":"publisher","unstructured":"Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 12, https:\/\/doi.org\/10.1126\/scitranslmed.abd3876 (2020).","DOI":"10.1126\/scitranslmed.abd3876"},{"key":"149_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-022-05273-0","volume":"611","author":"MC Woodruff","year":"2022","unstructured":"Woodruff, M. C. et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 611, 139\u2013147 (2022).","journal-title":"Nature"},{"key":"149_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283\u2013288 (2021).","journal-title":"Nature"},{"key":"149_CR12","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu, B., Huang, S. & Yin, L. The cytokine storm and COVID-19. J. Med Virol. 93, 250\u2013256 (2021).","journal-title":"J. Med Virol."},{"key":"149_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cca.2020.06.017","volume":"509","author":"P Song","year":"2020","unstructured":"Song, P., Li, W., Xie, J., Hou, Y. & You, C. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta 509, 280\u2013287 (2020).","journal-title":"Clin. Chim. Acta"},{"key":"149_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102791","volume":"20","author":"Y Adiguzel","year":"2021","unstructured":"Adiguzel, Y. Molecular mimicry between SARS-CoV-2 and human proteins. Autoimmun. Rev. 20, 102791 (2021).","journal-title":"Autoimmun. Rev."},{"key":"149_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/8359683","volume":"2024","author":"A Arevalo-Cortes","year":"2024","unstructured":"Arevalo-Cortes, A., Rodriguez-Pinto, D. & Aguilar-Ayala, L. Evidence for molecular mimicry between SARS-CoV-2 and human antigens: implications for autoimmunity in COVID-19. Autoimmune Dis. 2024, 8359683 (2024).","journal-title":"Autoimmune Dis."},{"key":"149_CR16","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao, B. et al. Reduction and functional exhaustion of t cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 11, 827 (2020).","journal-title":"Front. Immunol."},{"key":"149_CR17","doi-asserted-by":"publisher","unstructured":"Kusnadi, A. et al. Severely ill COVID-19 patients display impaired exhaustion features in SARS-CoV-2-reactive CD8(+) T cells. Sci. Immunol. 6, https:\/\/doi.org\/10.1126\/sciimmunol.abe4782 (2021).","DOI":"10.1126\/sciimmunol.abe4782"},{"key":"149_CR18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/imm.13603","volume":"168","author":"MH Goncalves-Pereira","year":"2023","unstructured":"Goncalves-Pereira, M. H. et al. Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases. Immunology 168, 684\u2013696 (2023).","journal-title":"Immunology"},{"key":"149_CR19","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.cell.2020.10.001","volume":"183","author":"BJ Meckiff","year":"2020","unstructured":"Meckiff, B. J. et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4(+) T Cells in COVID-19. Cell 183, 1340\u20131353.e1316 (2020).","journal-title":"Cell"},{"key":"149_CR20","doi-asserted-by":"publisher","unstructured":"Son, K. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir J. 61, https:\/\/doi.org\/10.1183\/13993003.00970-2022 (2023).","DOI":"10.1183\/13993003.00970-2022"},{"key":"149_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/cid\/ciab611","volume":"74","author":"J Seessle","year":"2022","unstructured":"Seessle, J. et al. Persistent symptoms in adult patients 1 year after coronavirus disease 2019 (COVID-19): a prospective cohort study. Clin. Infect. Dis. 74, 1191\u20131198 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"149_CR22","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/cid\/ciab890","volume":"74","author":"MJ Peluso","year":"2022","unstructured":"Peluso, M. J., Thomas, I. J., Munter, S. E., Deeks, S. G. & Henrich, T. J. Lack of antinuclear antibodies in convalescent coronavirus disease 2019 patients with persistent symptoms. Clin. Infect. Dis. 74, 2083\u20132084 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"149_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101783","volume":"56","author":"R Chang","year":"2023","unstructured":"Chang, R. et al. Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 56, 101783 (2023).","journal-title":"EClinicalMedicine"},{"key":"149_CR24","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1084\/jem.20181621","volume":"216","author":"HK Lim","year":"2019","unstructured":"Lim, H. K. et al. Severe influenza pneumonitis in children with inherited TLR3 deficiency. J. Exp. Med. 216, 2038\u20132056 (2019).","journal-title":"J. Exp. Med."},{"key":"149_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10875-021-01172-7","volume":"42","author":"G Bucciol","year":"2022","unstructured":"Bucciol, G. & Desmet, L. Leuven laboratory of inborn errors of, I., Corveleyn, A. & Meyts, I. Pathogenic P554S Variant in TLR3 in a patient with severe influenza pneumonia. J. Clin. Immunol. 42, 430\u2013432 (2022).","journal-title":"J. Clin. Immunol."},{"key":"149_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00439-020-02127-5","volume":"139","author":"SY Zhang","year":"2020","unstructured":"Zhang, S. Y. Herpes simplex virus encephalitis of childhood: inborn errors of central nervous system cell-intrinsic immunity. Hum. Genet. 139, 911\u2013918 (2020).","journal-title":"Hum. Genet."},{"key":"149_CR27","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1212\/WNL.0000000000000999","volume":"83","author":"HK Lim","year":"2014","unstructured":"Lim, H. K. et al. TLR3 deficiency in herpes simplex encephalitis: high allelic heterogeneity and recurrence risk. Neurology 83, 1888\u20131897 (2014).","journal-title":"Neurology"},{"key":"149_CR28","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1084\/jem.20101568","volume":"208","author":"Y Guo","year":"2011","unstructured":"Guo, Y. et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208, 2083\u20132098 (2011).","journal-title":"J. Exp. Med."},{"key":"149_CR29","doi-asserted-by":"publisher","unstructured":"Chen, J. et al. Inborn errors of TLR3- or MDA5-dependent type I IFN immunity in children with enterovirus rhombencephalitis. J. Exp. Med. 218, https:\/\/doi.org\/10.1084\/jem.20211349 (2021).","DOI":"10.1084\/jem.20211349"},{"key":"149_CR30","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1084\/jem.20161759","volume":"214","author":"IT Lamborn","year":"2017","unstructured":"Lamborn, I. T. et al. Recurrent rhinovirus infections in a child with inherited MDA5 deficiency. J. Exp. Med. 214, 1949\u20131972 (2017).","journal-title":"J. Exp. Med."},{"key":"149_CR31","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1084\/jem.20142274","volume":"212","author":"LL Andersen","year":"2015","unstructured":"Andersen, L. L. et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. J. Exp. Med. 212, 1371\u20131379 (2015).","journal-title":"J. Exp. Med."},{"key":"149_CR32","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1084\/jem.20180628","volume":"215","author":"N Hernandez","year":"2018","unstructured":"Hernandez, N. et al. Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. J. Exp. Med. 215, 2567\u20132585 (2018).","journal-title":"J. Exp. Med."},{"key":"149_CR33","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1126\/science.aaa1578","volume":"348","author":"MJ Ciancanelli","year":"2015","unstructured":"Ciancanelli, M. J. et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency. Science 348, 448\u2013453 (2015).","journal-title":"Science"},{"key":"149_CR34","doi-asserted-by":"publisher","unstructured":"Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, https:\/\/doi.org\/10.1126\/science.abd4570 (2020).","DOI":"10.1126\/science.abd4570"},{"key":"149_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01173-8","volume":"15","author":"D Matuozzo","year":"2023","unstructured":"Matuozzo, D. et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Med. 15, 22 (2023).","journal-title":"Genome Med."},{"key":"149_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29338","volume":"10","author":"N Saheb Sharif-Askari","year":"2024","unstructured":"Saheb Sharif-Askari, N. et al. Multiple inborn errors of type I IFN immunity in a 33-year-old male with a fatal case of COVID-19. Heliyon 10, e29338 (2024).","journal-title":"Heliyon"},{"key":"149_CR37","doi-asserted-by":"publisher","unstructured":"Kholaiq, H. et al. Human Genetic and immunological determinants of SARS-CoV-2 infection and multisystem inflammatory syndrome in children. Clin. Exp. Immunol. https:\/\/doi.org\/10.1093\/cei\/uxae062 (2024).","DOI":"10.1093\/cei\/uxae062"},{"key":"149_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4049\/jimmunol.129.1.1","volume":"129","author":"S Panem","year":"1982","unstructured":"Panem, S., Check, I. J., Henriksen, D. & Vilcek, J. Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129, 1\u20133 (1982).","journal-title":"J. Immunol."},{"key":"149_CR39","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1371\/journal.pmed.0030292","volume":"3","author":"M Levin","year":"2006","unstructured":"Levin, M. Anti-interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e292 (2006).","journal-title":"PLoS Med."},{"key":"149_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/289496a0","volume":"289","author":"A Vallbracht","year":"1981","unstructured":"Vallbracht, A., Treuner, J., Flehmig, B., Joester, K. E. & Niethammer, D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289, 496\u2013497 (1981).","journal-title":"Nature"},{"key":"149_CR41","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718\u2013724 (2020).","journal-title":"Science"},{"key":"149_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jaci.2020.04.029","volume":"146","author":"S Trouillet-Assant","year":"2020","unstructured":"Trouillet-Assant, S. et al. Type I IFN immunoprofiling in COVID-19 patients. J. Allergy Clin. Immunol. 146, 206\u2013208 e202 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"149_CR43","unstructured":"Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020)."},{"key":"149_CR44","doi-asserted-by":"publisher","unstructured":"Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, https:\/\/doi.org\/10.1126\/sciimmunol.abl4340 (2021).","DOI":"10.1126\/sciimmunol.abl4340"},{"key":"149_CR45","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","volume":"47","author":"R Koning","year":"2021","unstructured":"Koning, R. et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intens. Care Med. 47, 704\u2013706 (2021).","journal-title":"Intens. Care Med."},{"key":"149_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1327","volume":"10","author":"D Goncalves","year":"2021","unstructured":"Goncalves, D. et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. Clin. Transl. Immunol. 10, e1327 (2021).","journal-title":"Clin. Transl. Immunol."},{"key":"149_CR47","doi-asserted-by":"publisher","unstructured":"Lopez, J. et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J. Exp. Med. 218, https:\/\/doi.org\/10.1084\/jem.20211211 (2021).","DOI":"10.1084\/jem.20211211"},{"key":"149_CR48","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3201\/eid2907.230198","volume":"29","author":"RA Jacob","year":"2023","unstructured":"Jacob, R. A. et al. Sensitivity to neutralizing antibodies and resistance to type I interferons in SARS-CoV-2 R.1 lineage variants, Canada. Emerg. Infect. Dis. 29, 1386\u20131396 (2023).","journal-title":"Emerg. Infect. Dis."},{"key":"149_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102477","volume":"24","author":"A Banerjee","year":"2021","unstructured":"Banerjee, A. et al. Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. iScience 24, 102477 (2021).","journal-title":"iScience"},{"key":"149_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27318-0","volume":"12","author":"CF Hatton","year":"2021","unstructured":"Hatton, C. F. et al. Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Nat. Commun. 12, 7092 (2021).","journal-title":"Nat. Commun."},{"key":"149_CR51","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10875-021-01060-0","volume":"41","author":"SE Vazquez","year":"2021","unstructured":"Vazquez, S. E. et al. Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma. J. Clin. Immunol. 41, 1169\u20131171 (2021).","journal-title":"J. Clin. Immunol."},{"key":"149_CR52","doi-asserted-by":"publisher","unstructured":"Meisel, C. et al. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J. Clin. Investig. 131, https:\/\/doi.org\/10.1172\/JCI150867 (2021).","DOI":"10.1172\/JCI150867"},{"key":"149_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq1789","volume":"16","author":"BR Babcock","year":"2024","unstructured":"Babcock, B. R. et al. Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19. Sci. Transl. Med. 16, eadq1789 (2024).","journal-title":"Sci. Transl. Med."},{"key":"149_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03328-4","volume":"20","author":"M Rojas","year":"2022","unstructured":"Rojas, M. et al. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 20, 129 (2022).","journal-title":"J. Transl. Med."},{"key":"149_CR55","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/imr.12504","volume":"275","author":"P Borrow","year":"2017","unstructured":"Borrow, P. & Moody, M. A. Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol. Rev. 275, 62\u201378 (2017).","journal-title":"Immunol. Rev."},{"key":"149_CR56","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","volume":"23","author":"BF Haynes","year":"2023","unstructured":"Haynes, B. F. et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 23, 142\u2013158 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"149_CR57","doi-asserted-by":"publisher","first-page":"e0125618","DOI":"10.1371\/journal.pone.0125618","volume":"10","author":"K Kaur","year":"2015","unstructured":"Kaur, K. et al. High affinity antibodies against influenza characterize the plasmablast response in SLE patients after vaccination. PLoS ONE 10, e0125618 (2015).","journal-title":"PLoS ONE"},{"key":"149_CR58","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41577-019-0143-6","volume":"19","author":"F Krammer","year":"2019","unstructured":"Krammer, F. The human antibody response to influenza A virus infection and vaccination. Nat. Rev. Immunol. 19, 383\u2013397 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"149_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0443-0","volume":"15","author":"E Landais","year":"2018","unstructured":"Landais, E. & Moore, P. L. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 15, 61 (2018).","journal-title":"Retrovirology"},{"key":"149_CR60","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41590-022-01248-5","volume":"23","author":"H Qi","year":"2022","unstructured":"Qi, H., Liu, B., Wang, X. & Zhang, L. The humoral response and antibodies against SARS-CoV-2 infection. Nat. Immunol. 23, 1008\u20131020 (2022).","journal-title":"Nat. Immunol."},{"key":"149_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81862-9","volume":"11","author":"B Trinite","year":"2021","unstructured":"Trinite, B. et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci. Rep. 11, 2608 (2021).","journal-title":"Sci. Rep."},{"key":"149_CR62","doi-asserted-by":"crossref","unstructured":"Peluso, M. J. et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci. Adv. 7, eabh3409 (2021).","DOI":"10.1126\/sciadv.abh3409"},{"key":"149_CR63","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","volume":"23","author":"DM Altmann","year":"2023","unstructured":"Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. & Boyton, R. J. The immunology of long COVID. Nat. Rev. Immunol. 23, 618\u2013634 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"149_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103445","volume":"22","author":"FS Seibert","year":"2023","unstructured":"Seibert, F. S. et al. Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun. Rev. 22, 103445 (2023).","journal-title":"Autoimmun. Rev."},{"key":"149_CR65","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s10067-023-06670-0","volume":"42","author":"F Tesch","year":"2023","unstructured":"Tesch, F. et al. Incident autoimmune diseases in association with SARS-CoV-2 infection: a matched cohort study. Clin. Rheumatol. 42, 2905\u20132914 (2023).","journal-title":"Clin. Rheumatol."},{"key":"149_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53356-5","volume":"15","author":"AF Jernbom","year":"2024","unstructured":"Jernbom, A. F. et al. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat. Commun. 15, 8941 (2024).","journal-title":"Nat. Commun."},{"key":"149_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36686-8","volume":"14","author":"JR Jaycox","year":"2023","unstructured":"Jaycox, J. R. et al. SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Nat. Commun. 14, 1299 (2023).","journal-title":"Nat. Commun."},{"key":"149_CR68","volume":"2009","author":"ANW Maek","year":"2009","unstructured":"Maek, A. N. W. & Silachamroon, U. Presence of autoimmune antibody in chikungunya infection. Case Rep. Med. 2009, 840183 (2009).","journal-title":"Case Rep. Med."},{"key":"149_CR69","first-page":"202","volume":"20","author":"M Loza-Tulimowska","year":"1976","unstructured":"Loza-Tulimowska, M., Semkow, R., Michalak, T. & Nowoslawski, A. Autoantibodies in sera of influenza patients. Acta Virol. 20, 202\u2013207 (1976).","journal-title":"Acta Virol."},{"key":"149_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587380","volume":"11","author":"G Houen","year":"2020","unstructured":"Houen, G. & Trier, N. H. Epstein-barr virus and systemic autoimmune diseases. Front. Immunol. 11, 587380 (2020).","journal-title":"Front. Immunol."},{"key":"149_CR71","doi-asserted-by":"publisher","unstructured":"Gugliesi, F. et al. Human cytomegalovirus and autoimmune diseases: Where are we? Viruses 13, https:\/\/doi.org\/10.3390\/v13020260 (2021).","DOI":"10.3390\/v13020260"},{"key":"149_CR72","doi-asserted-by":"publisher","first-page":"E1030","DOI":"10.1503\/cmaj.230249","volume":"195","author":"TJ Murphy","year":"2023","unstructured":"Murphy, T. J. et al. The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023. CMAJ 195, E1030\u2013E1037 (2023).","journal-title":"CMAJ"},{"key":"149_CR73","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.3201\/eid2609.201495","volume":"26","author":"A Banerjee","year":"2020","unstructured":"Banerjee, A. et al. Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26, 2054\u20132063 (2020).","journal-title":"Emerg. Infect. Dis."}],"container-title":["npj Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00149-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00149-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:20Z","timestamp":1756902140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44298-025-00149-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["149"],"URL":"https:\/\/doi.org\/10.1038\/s44298-025-00149-2","relation":{},"ISSN":["2948-1767"],"issn-type":[{"value":"2948-1767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}